Literature DB >> 33660142

Lack of Evidence Does Not Equal Lack of Benefit: Neoadjuvant Chemotherapy and Trimodality Therapy in Selected Patients with Muscle-Invasive Bladder Cancer : In response to: Dirk Böhmer and Arne Grün. Lacking Evidence to Recommend Neoadjuvant Chemotherapy and Definitive Radiotherapy in Muscle-Invasive Bladder Cancer.

Di Maria Jiang1, Peter Chung2, Girish S Kulkarni3, Nick D James4,5, Srikala S Sridhar6.   

Abstract

Entities:  

Mesh：

Year:  2021        PMID： 33660142     DOI： 10.1007/s11912-021-01035-9

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN： 1523-3790            Impact factor:   5.075


× No keyword cloud information.
  8 in total

1.  Treatment of muscle invasive bladder cancer: evidence from the National Cancer Database, 2003 to 2007.

Authors:  Ugo Fedeli; Stacey A Fedewa; Elizabeth M Ward
Journal:  J Urol       Date:  2010-11-12       Impact factor: 7.450

2.  International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial.

Authors:  Gareth Griffiths; Reginald Hall; Richard Sylvester; Derek Raghavan; Mahesh K B Parmar
Journal:  J Clin Oncol       Date:  2011-04-18       Impact factor: 44.544

3.  Neoadjuvant Chemotherapy Before Bladder-Sparing Chemoradiotherapy in Patients With Nonmetastatic Muscle-Invasive Bladder Cancer.

Authors:  Di Maria Jiang; Haiyan Jiang; Peter W M Chung; Alexandre R Zlotta; Neil Eric Fleshner; Robert G Bristow; Alejandro Berlin; Girish S Kulkarni; Nimira S Alimohamed; Gregory Lo; Srikala S Sridhar
Journal:  Clin Genitourin Cancer       Date:  2018-10-04       Impact factor: 2.872

4.  Delivery of perioperative chemotherapy for bladder cancer in routine clinical practice.

Authors:  C M Booth; D R Siemens; Y Peng; I F Tannock; W J Mackillop
Journal:  Ann Oncol       Date:  2014-06-10       Impact factor: 32.976

5.  Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity.

Authors:  Elizabeth R Plimack; Jean H Hoffman-Censits; Rosalia Viterbo; Edouard J Trabulsi; Eric A Ross; Richard E Greenberg; David Y T Chen; Costas D Lallas; Yu-Ning Wong; Jianqing Lin; Alexander Kutikov; Efrat Dotan; Timothy A Brennan; Norma Palma; Essel Dulaimi; Reza Mehrazin; Stephen A Boorjian; William Kevin Kelly; Robert G Uzzo; Gary R Hudes
Journal:  J Clin Oncol       Date:  2014-05-12       Impact factor: 44.544

6.  Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates.

Authors:  Toni K Choueiri; Susanna Jacobus; Joaquim Bellmunt; Angela Qu; Leonard J Appleman; Christopher Tretter; Glenn J Bubley; Edward C Stack; Sabina Signoretti; Meghara Walsh; Graeme Steele; Michelle Hirsch; Christopher J Sweeney; Mary-Ellen Taplin; Adam S Kibel; Katherine M Krajewski; Philip W Kantoff; Robert W Ross; Jonathan E Rosenberg
Journal:  J Clin Oncol       Date:  2014-05-12       Impact factor: 44.544

Review 7.  Correlation of pathologic complete response with survival after neoadjuvant chemotherapy in bladder cancer treated with cystectomy: a meta-analysis.

Authors:  Fausto Petrelli; Andrea Coinu; Mary Cabiddu; Mara Ghilardi; Ivano Vavassori; Sandro Barni
Journal:  Eur Urol       Date:  2013-07-03       Impact factor: 20.096

8.  'Thursday's child has far to go'-interpreting subgroups and the STAMPEDE trial.

Authors:  M R Spears; N D James; M R Sydes
Journal:  Ann Oncol       Date:  2017-10-01       Impact factor: 32.976
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.